Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real-world Clinical Study of Pralsetinib in the Treatment of RET Fusion-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Prophylactic Use of Leukocyte-increasing Drug Leucogen

NCT07418879 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT07418879
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07418879 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real-world Clinical Study of Pralsetinib in the Treatment of RET Fusion-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Prophylactic Use of Leukocyte-increasing Drug Leucogen
Lead sponsor
Fudan University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
February 5, 2026
Completion date
December 31, 2028
Enrollment
25 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer, pralsetinib, ret fusion